Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165439 | 0.83 | LOXL2 (0.60) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL7169246 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL31059889 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL28338445 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL401081 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL29403791 | 0.82 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL28335219 | 0.80 | LOXL2 (0.67) | LOXL2AHRHRH3AOC3MTNR1A | |
| SCHEMBL5642064 | 0.79 | LOXL2 (0.60) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL2592547 | 0.79 | LOXL2 (0.60) | LOXL2AHRHRH3HRH4AOC3 | |
| SCHEMBL6860219 | 0.78 | LOXL2 (0.64) | LOXL2AHRHRH3HRH4AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | claimed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | claimed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | claimed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | disclosed |
| CN-115093408-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-09-23 | — | — | CN | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-4028130-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | Shionogi & Co., Ltd (JP) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| CN-114401965-A | Benzylamine-containing 5, 6-heteroaromatic compounds useful against mycobacterial infections | 盐野义制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0576357-A1 | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1993-12-29 | — | — | EP | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | LOXL2 3819/4885AHR 1045/4885HRH3 17/4885 |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | CYC1, MT-CO1, ABCB11 | LOXL2 4816/4885AHR 3623/4885HRH3 4501/4885 |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | LOXL2 4550/4885AHR 313/4885HRH3 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.